LAB ANIMAL RESEARCH EQUIPMENT

**INEXPENSIVE EXERCISER**
- For rats and mice -- 4-lane exerciser.
- Electronically controlled speed.
- Electric stimulation grids.

**Grip Strength Meter for rats and mice**
- Objectively measures animal deficiency in strength.

**End Tidal CO₂ Meter**
- Can be used for Rats
- Extremely small air sample flow -- 5ml/min.
- Analog output to most recorders.
- Digital display N₂O measurements.

**Inexpensive Animal Activity Meters**
- "Mini" activity meter uses standard plastic cages.
- Can be used with rats or mice.
- 15 Infrared sensors.
- Separates ambulatory from total activity.
- Multi-cage system available w/ IBM-PC interface.

**Cardiac Output for Rats**
- Thermodilution method using 1/3 mm temp. microprobes.
- Can be interfaced to an IBM-PC.
- Measures: CO, S.V, BP, Mean Transit Time, Ejection Fraction and much more.

**Ventilators**
- Mechanical (piston) positive pressure ventilators for rodents and larger animals.

**Economical O₂/CO₂ Metabolic System**
- O₂ Consumption/CO₂ production computer (IBM-PC).
- Open-circuit indirect calorimeter.
- Completely computerized.
- Single channel.
- Also available-multi-channel systems for rats, mice, bacteria, horses, and humans.

**256 Point Thermometer**
- Interface to IBM-PC for 1 to 256 thermocouples.
- Variety of temp. probes (rectal, skin, implantable).
- Software provides graphics and real-time plotting.
- Also special software for Pyrogenic Activity studies.

**Mazes -- "Figure 8" and "Radial Arm"**
- Computerized system with universal maze software (for IBM-PC) monitors interruption of 128 IR sensors.
- Data LOTUS 1-2-3 compatible.

**Video Trackers for Water Mazes**
- Measures activity, distance traveled, pattern of movement, & rotations of multiple animals w/ 1 TV camera.
- Vertical activity (3-D) measurements w/ 2 cameras.
- Ideal for water maze, human and animal gait analysis.

For our complete catalog please contact: Columbus Instruments International Corp.
P.O. Box 44049  Columbus, Ohio 43204  USA
PH: (614) 488-6176  FAX: (614) 276-0529  TLX: 246514  Toll Free: 1-800-669-5011
NOW AVAILABLE!

The New Edition of Goodman and Gilman's
THE PHARMACOLOGICAL BASIS
OF THERAPEUTICS 8th Edition

Edited by
Alfred Goodman Gilman, MD, PhD,
University of Texas, Southwestern
Medical Center at Dallas
Theodore W. Rall, PhD, University
of Virginia School of Medicine
Alan S. Nies, MD, University of
Colorado School of Medicine
Palmer Taylor, PhD, University of
California, San Diego

The new edition of this highly acclaimed text follows in the
tradition of excellence that professionals have come to expect from Goodman
and Gilman. It has been completely revised and updated
by leading, international authorities in the field. Sections on
general principles; gastrointestinal pharmacology; autacoids
and drug therapy of inflammation; benzodiazepines and
cholinergic pharmacology have been expanded and re-
organized. New chapters and discussions include the ad-
varces in antiviral agents (including AZT) and the treatment
of AIDS; thrombolytic and antiplatelet drugs (including
the use of anticoagulants, tissue plasminogen activator
and streptokinase); hematopoietic growth factors; new
converting enzyme (ACE) inhibitors and calcium channel
blockers, and anti-fungal agents.

INDEPENDENT OPINIONS
"... The great achievement of
Goodman and Gilman is that students
and experts alike have come to rely on
it as an authoritative reference. It is a
masterful job. I cannot praise it too
highly."
—Adele B. Rifkind, MD, Prof. of Pharm.,
Cornell Univ. Med. Center

"I was very pleased to see that the
quality of the previous editions has
been maintained. I will recommend
this text for use not only by colleagues
in pharmacology and medicine, but also
for use in our teaching programs."
—Robert B. Diasio, MD, Prof. of Med. and
Pharm., Chair, Dept. of Pharm., Univ. of
Alabama at Birmingham

SECTION HEADINGS
General Principles • Drugs Acting at Synaptic and Neuroeffector
Junctional Sites • Drugs Acting on the Central Nervous System
• Autacoids: Drug Therapy of Inflammation • Water, Salts,
and Ions • Drugs Affecting Renal Function and Electrolyte
Metabolism • Cardiovascular Drugs • Drugs Affecting
Gastrointestinal Function • Drugs Affecting Uterine Motility •
Chemotherapy of Parasitic Infections • Chemotherapy of
Microbial Diseases • Chemotherapy of Neoplastic Diseases •
Drugs Used for Immunosuppression • Drugs Acting on the
Blood and the Blood-Forming Organs • Hormones and Hormone
Antagonists • The Vitamins • Dermatology • Toxicology •
Appendix I • Appendix II •
1830 pp. 1990 ISBN: 0-08-040296-8 US$ 89.50

Prices are subject to change without notice. US Dollar prices quoted are valid for customers in North and South America only.
Prices for all other countries are available from the appropriate Pergamon office.
Contact: Pergamon Press Order Dept., 100 Front Street, Box 500, Riverside, NJ 08075-7500. To order by phone, call
toll-free 1-800-257-5755 (9:00 a.m. to 5:00 p.m. EST) or FAX orders, 1-800-562-1272.
Canadian Residents, for price and ordering information, please contact: Collier Macmillan Canada, Inc., 539 Collier
Macmillan Drive, Cambridge, Ontario, N1R 5W9, Canada, Tel: (519) 740-2222; FAX: (519) 740-8408.
Residents of Japan, for price and ordering information, please contact: Igaku-Shoin, 1-28-38 Hongo Bunkyo-ku, Tokyo, Japan.
Outside the United States, Canada and Japan, please contact:
Pergamon Press Ltd, Headington Hill Hall, Oxford OX3 0BW, England

ORDER YOUR COPY TODAY!

PERGAMON PRESS
Member of Maxwell Macmillan Pergamon Publishing Corporation
AUTHOR INDEX

Abbate, G. M., 230
Akaike, N., 169
Albrighton-Winslow, C. R., 335
Allain, G., 297
Allen, J. C., 297
Arrowmith, J. E., 318
Atchison, W. D., 159, 236
Bauer, J. A., 249
Becherucci, C., 29
Bemis, K. G., 222
Bitran, D., 259
Blackburn, K. J., 318
Blandina, P. A., 341
Bock, M. G., 304
Bonanno, G., 88
Borowsky, B., 204
Branch, R. A., 56
Brannan, M. D., 279
Breaux, A. P., 94
Brickson, B., 335
Brooks, D. P., 335
Brown, E. E., 119
Brown, N. J., 56
Bryan, W. M., 335
Buckpitt, A., 391
Burges, R. A., 318
Caldwell, N., 335
Carpenedo, F., 234
Carroll, F. I., 365
Carson, J. R., 279
Cernichiarri, E. I.
Cervoni, P., 164
Chan, Y. L., 309
Chang, B., 38
Chao, C. C., 255
Chávez, E., 385
Cineseschmidt, B. V., 304
Cohen, M. L., 103
Cohen, S., 189
Cone, E. J., 211
Corr, P. B., 325
Costa, G., 127
Coyle, J. T., 402
Cross, P. E., 318
Dage, R. C., 358
Dahm, L. J., 412
Dalrymple, H. W., 318
Damiano, B. P., 279
Dansma, G., 119
DiPette, D. J., 110
Dwyer, T. M., 141
Dykstra, L. A., 149
Ertel, P. J., 222
Farley, J. M., 141
Fedele, E., 88
Fibiger, H. C., 119
Finlay, J. M., 119
Flaim, S. F., 279
Flavahan, N. A., 50
Floreani, M., 243
Fok, K. F., 193
Fontana, G., 88
Freidinger, R. M., 304
Fujino, K., 371
Fukuta, T., 378
Fung, H.-L., 249
Furuya, Y., 76
Gaginella, T. S., 266
Garcia, H. F., 297
Garcia-Pascual, A., 127
Garcia-Sacristán, A., 127
Gekker, G., 255
Gelein, R. M., 1
Gemignani, A., 88
Gill, A., 279
Gleason, M. M., 279
Goldfarb, J., 341
Goodwin, R. M., 94
Green, J. P., 341
Greer, M. A., 135
Greer, S. E., 135
Grimshaw, M. B., 266
Gullikson, G. W., 266
Gwilt, M., 318
Hahn, R. A., 94
Han, S.-P., 183
Harsing, L. G. Jr., 44
Hedberg, A., 279
Herman, A. G., 194
Higgs, A. J., 318
Ho, P. P. K., 94
Holguin, J. A., 385
Holtzman, S. G., 62
Huang, Y. F., 69
Huang, Z.-J., 38
Huffman, W. F., 335
Ichikawa, J., 348
Imanishi, M., 11
Inari, K., 378
Inoue, I., 371
Ishii, K., 38
Ishimaru, H., 378
Isla, M., 127
Itoh, Z., 272
Iwanaga, Y., 272
Jimenez, E., 127
Kameyama, T., 378
Kanekal, S., 391
Kaneko, T., 76
Kato, K., 402
Kato, A., 378
Katzka, D. A., 189
Kellogg, C. K., 259
Kerwin, J. F., Jr., 38
Kimura, I., 18, 24
Kimura, M., 18, 24
King, A. D., 189
Kinter, L. B., 335
Kiss, I., 365
Knuepfer, M. M., 183
Kondoh, T., 18, 24
Kreulen, D. L., 82
Kuhn, C. M., 204
Lai, F. M., 164
Lawrence, W. B., 176
Levesque, P. C., 236
Lewin, A. H., 365
Lewis, D. V., 289
Lis, E. V., 304
Lowensohn, R. I., 304
Lucaites, J. V., 103
Lyons, W. E., 402
MacDonald, B. R., 94
Mante, S., 62
Mather, L. E., 69
Matson, C. F., 176
McAdams, S., 335
McCullough, J. R., 279
Meehan, A. G., 92
Meltzer, H. Y., 348
Mendelsohn, L. G., 103
Mihelich, E. D., 94
Miller, J. A., 358
Minneman, K. P., 62
Miranda, M. E., 385
Miura, G. A., 176
Miura, K., 11
Miyoshi, Y., 371
Mizumoto, A., 272
Molitor, T. W., 255
Moore, M. L., 335
Morin, D., 391
Moumni, C., 266
Mugridge, K. G., 29
Murai, M., 38
Murase, K., 378
Murtough, M. P., 255
Nabeshima, T., 378
Nair, X., 365
Nakaya, S., 371
Nakaya, Y., 371
Nakazawa, T., 76
Namb, P., 335
Navran, S. S., 297
Negus, S. S., 149
Nickols, G. A., 110
Nieduzak, T. R., 230
Ogita, K., 378
Okamura, M., 11
Ohtsuka, H., 378
Osorno, A., 385
Pace, J. G., 176
Parente, L., 29
Perretti, M., 29
Peterson, P. K., 255
Pettrini, M. F., 141
Pettibone, D. J., 304
Picker, M. J., 149
Plopper, C., 391
Porter, J., 56
Primus, R. J., 259
Puttfarken, P. S., 402
Quigley, J., 365
Raineri, M., 68
Ramp, D., 358
Reiss, D. R., 304
Reynolds, J. C., 189
Robertson, D. W., 222
Robinson, N. A., 176
Roca-Cusachs, A., 110
Roth, R. A., 412
Runciman, W. B., 69
Ryder, D., 56
Sato, N., 135
Schmidt, C. J., 230
Schultze, A. E., 412
Secrest, R. J., 103
Seidel, C. L., 297
Shank, R. P., 279
Shieh, C.-C., 141
Shimmen, T., 11
Shimokawa, H., 50
Simpson, P. J., 94
Spitabergen, J. M., 159
Stassen, F. L., 335
Steinberg, M. I., 222
Suarez, T., 94
Takahashi, K., 169
Tanikella, T., 164
Taylor, V. L., 230
Totoro, J. A., 304
Towner, R. D., 94
Tramposch, K. M., 365
Trapani, A. J., 183
Tsukimi, H., 18, 24
Tung, R. D., 304
Upton, R. N., 69
Van Diest, M. J., 194
Vanhoutte, P. M., 50
Vaupeil, D. B., 211
Veber, D. F., 304
Velayo, L., 358
Verbeuren, T. J., 194
Vizi, E. S., 44
Wagenar, F. L., 38
Wakatsuki, T., 371
Walcott, J., 341
Wang, L., 94
Wang, T., 309
Wang, X., 135
Westfall, T. C., 183
Wiest, S. A., 222
Williams, P. D., 304
Wong, J. T. F., 119
Woyden, C. J., 304
Xie, C.-W., 289
Yamamoto, K., 11
Yamanaka, S., 11
Yamashita, Y., 11
Yamatsu, K., 76
Yoneda, Y., 378
Yoshida, N., 272
Yukimura, T., 11
Zalups, R. K., 1
Zazueta, C., 385
Zimmerman, K. M., 222
Zuanetti, G., 325
Notice to Contributors

(Revised July 1, 1986)

Scope of Submitted Manuscripts

The Journal invites for review original papers dealing with interactions of chemicals with biological systems. Any aspect of pharmacology and therapeutics is included, but descriptive case reports without dose response or mechanism studies are not accepted. Manuscripts dealing primarily with new methods will be reviewed only if data are presented showing new or more reliable pharmacological information has been obtained by use of the methods.

Submission of Manuscripts

Submit four copies to Dr. Eva King Killam, Editor in Chief, Journal of Pharmacology and Experimental Therapeutics, Department of Pharmacology, School of Medicine, University of California, Davis, California 95616, and accompanied by a check or purchase order for $30.00 manuscript handling fee (in U.S. funds payable to ASPET). If submission of the manuscript handling fee entails personal financial hardship to the author, the fee will be waived. In that event the authors should submit a request for waiver of the fee at the time the manuscript is submitted. Only one copy of rejected manuscripts will be returned. If extra copies of figures are needed, a request must be made at the time the manuscript is submitted.

Manuscripts should be typewritten double spaced in the English language using one side only of approximately 21.6 by 28 cm paper. One original drawing or photograph of each line figure and three (3) clear copies will be sufficient, 4 original drawings or photographs are required of each half-tone figure. Pages should not be stapled together.

It is understood that neither the manuscript nor the data it contains have been previously published nor are being submitted elsewhere for publication. Manuscripts are accepted for review with the understanding that all authors listed have approved submission of the paper and that persons cited for unpublished work have approved such citation.

Authors submitting a manuscript do so with the understanding that if it is accepted for publication, copyright in the article, including the right to reproduce the article in all forms and media, shall be assigned exclusively to the Society for Pharmacology and Experimental Therapeutics. No reasonable request by the author for permission to reproduce any of his or her contributions to the journal will be refused. It will be necessary for all authors to sign an assignment of copyright form which will be mailed from the Editorial Office on acceptance of the manuscript. The only exceptions will be manuscripts on work done by employees of the U.S. Federal Government.

Organization of the Manuscript

In most cases manuscripts should contain the following sections in the order listed: 1) title page; 2) running title page; 3) abstract; 4) introduction; 5) methods; 6) results; 7) discussion; 8) acknowledgments; 9) references; 10) footnotes; 11) tables; 12) legends for figures; 13) figures; and 14) index terms. Each section should begin on a new page and all pages should be numbered consecutively.

1. Title page. This should contain the complete title of the manuscript, the names of all authors and the laboratory of origin.

2. Running title page. 1) Each published paper needs a running title to appear at the top of each page in the Journal. The running title should contain no more than 55 spaces, including punctuation. It should convey the sense of the full title. Commonly used abbreviations (such as "ATP," "ACH," etc.) may be used in the running title. 2) This page should also contain the name, address and telephone number of the person to whom page proof should be sent. 3) A list of abbreviations used in the paper should appear on this page. Additionally, each abbreviation should be defined the first time it is used in the text.

3. Abstract. The abstract should present in a concise form the purpose, the general methods, the findings and the conclusions of the manuscript. Abstracts should be limited to 200 words; abstracts of more than 250 words will not be accepted.

4. Introduction. This section should not be labeled, but should begin on a new page. It should contain a clear statement of the aims of the reported work or of the hypotheses which the work was designed to test. A brief account of the background of the reported work may also be given in this section.

5. Methods. This section should contain explicit, concise descriptions of all new methods or procedures employed. Modifications of previously published methods should be described. Commonly used methods require only a citation of the original source. When methods are described, the description should be such as to enable the reader to judge their accuracy, reproducibility and reliability and to repeat the experiment. Very extended descriptions of methods should be submitted as a supplement to the American Society for Information Science National Auxiliary Publications Service (NAPS) c/o Microfiche Publications, P.O. Box 3513, Grand Central Station, New York, NY 10017. A text reference or footnote stating that the full description is available from NAPS permits interested readers to obtain the information, and does not occupy an inordinate amount of Journal space. There is a nominal charge to authors for this procedure; those who request the complete information from NAPS pay a small fee.

6. Results. This section ordinarily contains the experimental data to be presented but not extended discussions of their significance. Results should usually be presented in graphic or tabular form, rather than discursively. Graphic presentation of data is often preferred but there should not be duplication in text, tables and figures. Sufficient data must be given to allow readers to judge the variability and reliability of the results. Statistical tests used and the data analyzed should be explained so that the findings can be interpreted and evaluated.

7. Discussion. This section should present conclusions to be drawn from the results. Speculative discussion is not discouraged, but the speculation should be based on the data presented and identified as such. The discussion should be as concise as possible, within the limits of the ideas which the authors wish to propose and adequate discussion of related work by others.

8. Acknowledgments. These may be included at the end of the text of the manuscript, but should have a separate heading. Gifts and assistance can be acknowledged here but financial support should appear in a footnote to the title.

9. References. In text citations, give the author's name and the year of publication (e.g., McCarthy, 1952; Ruth and Gehrig, 1929). With more than two authors, the text citation should contain the name of the first author, followed by "et al.," and the date (e.g., Kennedy et al., 1960). In the list of references, entries should be arranged alphabetically by author, and not numbered. All authors' names should be given. If reference is made to more than one publication by the same authors in the same year, suffices (a, b, c, etc.) should be added to the year in the text citation and in the list of references.

The list of references should contain, in sequence, the following information: authors' names and initials, title of the cited article, title of the journal in which the article appeared (abbreviated; see below), volume number of the journal, inclusive pagination and year of publication. Abbreviations for journals should conform to the Biosis List of Serials (Biosciences Information Services of Biological Abstracts, Philadelphia, PA 19103). Citations of personal communications, unpublished observations and papers submitted for publication should be given in parentheses at the appropriate place in the text not in the list of references. A paper may not be cited as "in press" unless it has been accepted for publication. In such cases the name of the journal must be given.

No more than four references should be cited in support of any given point. The authors are responsible for the accuracy of such citations and are urged to take the utmost care in proofreading citations and reference list.

10. Footnotes. All footnotes to the title, authors' names or text should be indicated by arabic numeral superscripts, not by letters or other symbols. The footnotes should be typed in sequence on a separate page not a text page. Footnotes to tables are discussed under Tables, below.
11. Tables. Each table should be on a separate page. Tables should be numbered consecutively with arabic numerals, and should be designed to fit the page or column size of the Journal. A brief descriptive title should be given at the top of each table. The table number should be given in capital letters, the title in boldface upper and lower case letters (e.g., TABLE 3. Uptake of labeled drug by rat liver slices). The footnotes to the tables should be referenced by italicized lower case superscript letters (a, b, c, etc.) and should appear beneath the table involved, not on a separate page of the manuscript. Extensive tabular material not absolutely essential to the manuscript will be accepted for deposit with the ASIS/NAPS (see "Methods," above). In such instances a footnote in the published paper will refer the interested readers to NAPS from which copies may be obtained. Note Statistics below for expressions of probability.

12. Legends for figures. These should be numbered consecutively in arabic numerals and should appear on a separate page of the manuscript. Legends should explain the figures in sufficient detail so that frequent referral to the text is unnecessary, but efforts should be made to avoid unnecessary length. Abbreviations in the legends should conform to those in the text (see "Abbreviations," below).

13. Figures. Illustrations should be submitted as unmounted glossy photographic prints, no larger than 8 by 10 inches. The authors' name and address and the number of the figure should be placed on the back of each print. A typed label is usually most satisfactory. Ball type pen should not be used. Note Statistics below for expression of probability. Illustrations must be clear enough to permit reproduction without retouching and legibility after reduction to single-column size (approximately 3½ inches in width). Uniform symbolism should be used for all illustrations in a manuscript. Symbols, numbers and letters in the illustrations must be at least 1.5 mm in height after reduction to single column size. The title of each figure should appear in the legend rather than on the figure itself. Photomicrographs and electron micrographs should be labeled with a magnification calibration in micro or Angstrom units. A statement of the magnification should appear in the figure legend.

14. Index Terms. A list of index terms useful in constructing the annual index should be included as the last page of the manuscript.

Statistics.

Wherever possible statistical probability (P) in tables, figures, and figure legends should be expressed as * P < .05, ** P < .01 and *** P < .001. For second comparisons the symbols † may be used similarly. Authors are urged to avoid unnecessary complexity and to be consistent within the manuscript. In the event of multiple comparisons within a table, footnotes, a, b, c, etc. should be used.

Abbreviations

Magnitudes of variables reported should be expressed in numerals. Most abbreviations are used without punctuation, with no distinction between singular and plural forms (e.g., 1 mg, 25 mg; 1 sec, 25 sec). The usual prefixes are to be used for multiples or submultiples of the basic units (e.g., kg, g, mg, μg, ng pg). The following abbreviations, or their properly prefixed multiples or submultiples, may be used without definition in the text, tables and figures:

Units of length or volume

- meter m
- micron μ
- Angstrom Å
- liter (spell out in text)

Units of time

- hour hr or h
- minute min or m
- second sec or s

Kinetics

- dissociation constant \( K_d \)
- Dissociation constant of
  - enzyme substrate complex \( K_c \)
  - enzyme inhibitor complex \( K_i \)
- Michaelis constant \( V_{max} \)
- maximum initial velocity \( V_{max} \)

Miscellaneous

- degrees of temperature °C
- gravity g
- median doses \( \text{LD}_{50}, \text{ED}_{50}, \text{etc.} \)
- optically isometric forms d-, l-, dl-
- routes of drug administration i.v., i.p, s.c., i.m.
- standard deviation S.D.
- standard error S.E.

Whenever an abbreviation other than those above is to be used in a manuscript, it is to be defined in the text or in a footnote thereto, the first time it is used. Abbreviations for commonly used substances should be those recommended by the Journal of Biological Chemistry. Abbreviations for drugs may be used if properly defined on first use and if the chemical or generic name of the drug is given when the abbreviation is first used. Abbreviations may be used in the running title but not in the full title of the manuscript.

Drugs

Generic names should be used in text, tables and figures. Trade names may be mentioned in parentheses in the first text reference to the drug but should not appear in titles, figures or tables. When a trade name is used, it should be capitalized; generic or chemical names are not capitalized. The chemical nature of new drugs must be given when it is known. The form of drug used in calculations of doses (e.g., base or salt) should be indicated. When several drugs are used, it may save space to include a separate paragraph in "Methods," or a separate table or footnote, listing the relevant information about all drugs employed.

Page Charges

Authors are assessed page charges at the rate of $30 per printed page. With the page proof, authors will receive a request for information concerning such charges. These charges will be assessed only if they involve no personal expense to the authors. Request for waiver should be addressed to the ASPET Executive Officer at the time billing is received.

The cost of a limited number of illustrations will be borne by the Journal: the cost of excessive numbers of illustrations and of colored illustrations will have to be defrayed by the authors.

Experimental Subjects

The Society for Pharmacology & Experimental Therapeutics requires authors to affirm that original studies reported in Journals of the Society have been carried out in accordance with the Declaration of Helsinki and with the Guide for the Care and Use of Laboratory Animals as adopted and promulgated by the National Institutes of Health.
BOEHRINGER INGELHEIM
CENTENNIAL FELLOWSHIPS
IN CLINICAL PHARMACOLOGY

To advance research and knowledge in this vital field of medical science, Boehringer Ingelheim Pharmaceuticals, Inc. will award each year a limited number of Fellowships for terms of up to two years.

The purpose of the Boehringer Ingelheim Fellowships in Clinical Pharmacology is to identify outstanding physicians who are already qualified for a career in academic medicine, teaching and research, and to provide the extra training needed to equip them for a full-time academic career in Clinical Pharmacology in the United States.

Fellowships will be awarded to provide training at U.S. universities that have established training facilities in Clinical Pharmacology and a training program that, in general, meets the draft ASCPT "Proposed Requirements for Accreditation of Clinical Pharmacology Training Programs." The primary affiliation of the Fellows must be in the Clinical Pharmacology program. Competitive stipends are available.

For further information, write:

William M. Wardell, M.D., Ph.D.
Vice President - Medical Director
Boehringer Ingelheim Pharmaceuticals, Inc.
90 East Ridge - P.O. Box 368
Ridgefield, CT 06877

TIME TO RENEW?

To ensure uninterrupted service, please renew your journal subscription two months prior to the expiration date of your current subscription. To avoid renewal notices and price increases, consider a multiyear subscription. Current rates are available for up to three years.

For assistance with your renewal, call TOLL-FREE:

1-800-638-6423
(from anywhere in the U.S.)

Or write:
Subscription Fulfillment Department
428 East Preston Street
Baltimore, MD 21202

Williams & Wilkins
at your service.